Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Chongqing Zhifei Biological Products Co., Ltd.
  6. News
  7. Summary
    300122   CNE100000V20

CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.

(300122)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Chongqing Zhifei Biological Products : China trials mixing of CanSinoBIO's and Zhifei Longcom's COVID-19 vaccines -data

04/19/2021 | 09:17am EDT

BEIJING, April 19 (Reuters) - Chinese researchers are testing the mixing of COVID-19 vaccine doses developed by CanSino Biologics and a unit of Chongqing Zhifei Biological Products, according to clinical trial registration data.

Earlier this month, the director of the Chinese Center for Disease Control and Prevention said the country was "formally considering" giving people COVID-19 vaccine doses developed with different technologies as a way of further boosting efficacy.

A trial expected to involve 120 participants will test the safety and ability to trigger immune response of a dose of CanSinoBIO's Ad5-nCoV treatment, followed by a dose of ZF2001 from Anhui Zhifei Longcom Biopharmaceutical at a 28-day or 56-day interval, according to clinical trial record site ClinicalTrials.gov, which is maintained by a department under the National Institute of Health of the United States.

The trial is sponsored by disease control authorities in the eastern province of Jiangsu, where it is taking place, according to the record.

CanSinoBIO and Chongqing Zhifei Biological Products were not immediately available for comment.

Both vaccines are already being used in China's mass vaccination drive.

CanSinoBIO said interim data from overseas Phase III clinical trials showed its Ad5-nCoV vaccine was 68.83% effective at preventing symptomatic COVID-19 disease two weeks after one injection, while efficacy four weeks after one shot fell to 65.28%.

Chinese researchers are also running trials on a two-dose Ad5-nCoV regimen, as well as an inhaled version of the vaccine.

The inhaled vaccine could achieve the same effect as one injection with a much smaller dosage, local media The Paper reported on Monday, citing an interview with CanSinoBIO chief executive Yu Xuefeng.

No efficacy data has been made available from Phase III trials for Zhifei Longcom's ZF2001 vaccine, which requires three doses when used on its own. (Reporting by Roxanne Liu and Ryan Woo; Editing by Kenneth Maxwell, Kirsten Donovan)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
CANSINO BIOLOGICS INC. 10.39% 369.8 End-of-day quote.109.52%
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. 5.63% 193.3 End-of-day quote.30.69%
All news about CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
06/09China to study using CanSinoBIO COVID shots as a booster
RE
05/06Shares of China vaccine makers slump on U.S. waiver support
RE
04/19CHONGQING ZHIFEI BIOLOGICAL PRODUCTS : China trials mixing of CanSinoBIO's and Z..
RE
03/15CHONGQING ZHIFEI BIOLOGICAL PRODUCTS : China IMCAS's COVID-19 vaccine obtained e..
RE
02/02Sinopharm's COVID-19 vaccine remained active against S.Africa variant, effect..
RE
2020China's CAS COVID-19 vaccine induces immune response in mid-stage tests
RE
2020MY E G SERVICESá : MyEG Services Partners With Anhui Zhifei Longcom for Covid-19..
MT
2020Hong Kong stocks end higher as investors bet on vaccine progress
RE
2020China stocks end lower after U.S. House clears delisting bill
RE
2020China stocks falter as U.S. House clears delisting bill
RE
More news
Financials
Sales 2021 26 117 M 4 083 M 4 083 M
Net income 2021 7 311 M 1 143 M 1 143 M
Net cash 2021 7 659 M 1 197 M 1 197 M
P/E ratio 2021 42,3x
Yield 2021 0,63%
Capitalization 309 B 48 336 M 48 350 M
EV / Sales 2021 11,5x
EV / Sales 2022 9,07x
Nbr of Employees 3 380
Free-Float 14,7%
Chart CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
Duration : Period :
Chongqing Zhifei Biological Products Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Average target price 219,11 CNY
Last Close Price 193,30 CNY
Spread / Highest target 30,6%
Spread / Average Target 13,4%
Spread / Lowest Target -9,36%
EPS Revisions
Managers and Directors
NameTitle
Ren Sheng Jiang Chairman & General Manager
Zhen Jing Li Chief Financial Officer & Director
Yu Qin Wu Chairman-Supervisory Board
Xin Rong Zhang Independent Director
Bao Kui Liu Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.30.69%48 336
CSL LIMITED4.75%103 884
WUXI BIOLOGICS (CAYMAN) INC.21.40%67 880
BIOGEN INC.61.99%59 716
SAMSUNG BIOLOGICS CO.,LTD.2.30%50 040
ALEXION PHARMACEUTICALS, INC.16.26%40 148